SELLAS Life Sciences (SLS) Free Cash Flow Growth (1y) (2011 - 2026)
SELLAS Life Sciences (SLS) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 137.65% |
| 10 | SELLAS Life Sciences | 1.88 Bn | 1.77 Bn | - | 2.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.98% |
| Dec 31, 2025 | 31.05% |
| Sep 30, 2025 | 9.45% |
| Jun 30, 2025 | 24.29% |
| Mar 31, 2025 | 15.71% |
| Dec 31, 2024 | -48.25% |
| Sep 30, 2024 | -13.26% |
| Jun 30, 2024 | -27.97% |
| Mar 31, 2024 | 11.26% |
| Dec 31, 2023 | 6.35% |
| Sep 30, 2023 | -19.94% |
| Jun 30, 2023 | -31.33% |
| Mar 31, 2023 | -69.61% |
| Dec 31, 2022 | -3.54% |
| Sep 30, 2022 | 2.25% |
| Jun 30, 2022 | -17.62% |
| Mar 31, 2022 | 30.37% |
| Dec 31, 2021 | -245.33% |
| Sep 30, 2021 | -61.97% |
| Jun 30, 2021 | -44.87% |